A Phase II Study of CPX-351 Monotherapy in Acute Myeloid Leukemia
Latest Information Update: 08 Mar 2024
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms CPX-351 TA-SMP
- 08 Mar 2024 Status changed from recruiting to completed.
- 12 Dec 2023 interim Results (n=29 ) from prospective part , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 30 Nov 2023 According to a Jazz Pharmaceuticals plc media release, data from this trial will be presented at the at the 65th Annual American Society of Hematology (ASH) Annual Meeting.